ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Endometrial Cancer
Breast Cancer
Fallopian Tube Cancer
Carcinoma
Triple Negative Breast Cancer

Ovarian Cancer trials near Hanyang, Seoul, KOR:

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian...

Enrolling
Ovarian Cancer
Drug: Trastuzumab Deruxtecan
Drug: Bevacizumab

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Seoul, South Korea and 58 other locations

This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have prog...

Enrolling
Ovarian Cancer
Drug Related Neoplasm/Cancer
Drug: chemotherapy
Procedure: secondary cytoreductive surgery

Phase 2

Korea University

Seoul, Korea, Republic of

adult subjects with CA125-associated, advanced recurrent epithelial ovarian, fallopian tube or peritoneal carcinoma (FIGO Stage III/IV) with...

Enrolling
Ovarian Cancer Stage IV
Ovarian Cancer by FIGO Stage
Drug: Bevacizumab
Drug: Carboplatin

Phase 1, Phase 2

CanariaBio

Seoul, Korea, Republic of and 5 other locations

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Placebo to match olaparib 300mg
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 125 other locations

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Bevacizumab
Drug: Durvalumab placebo

Phase 3

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 213 other locations

the pharmacokinetics and safety of BR2022 and BR2022-1 in Patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian...

Enrolling
Ovarian Cancer
Drug: Olaparib 150 MG

Phase 1

Boryung

Seoul, Seoul, South Korea

of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...

Active, not recruiting
Ovarian Cancer
Drug: Alpelisib
Drug: Pegylated liposomal doxorubicin (PLD)

Phase 3

Novartis
Novartis

Seoul, South Korea and 92 other locations

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Seoul, South Korea and 176 other locations

therapy for the treatment of participants with advanced/recurrent ovarian cancer.Substudy 1 will investigate the safety, tolerabili...

Enrolling
Advanced/Recurrent Ovarian Cancer
Drug: Saruparib

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Seoul, South Korea and 22 other locations

as "study drug". The study is focused on patients who have advanced ovarian cancer.The aim of the study is to see how safe, tolerab...

Enrolling
Ovarian Cancer
Drug: Bevacizumab
Drug: Sarilumab

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Seoul, South Korea and 21 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems